230 related articles for article (PubMed ID: 10741696)
1. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Yang LY; Li L; Jiang H; Shen Y; Plunkett W
Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
4. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Peters GJ; Van Moorsel CJ; Lakerveld B; Smid K; Noordhuis P; Comijn EC; Weaver D; Willey JC; Voorn D; Van der Vijgh WJ; Pinedo HM
Int J Oncol; 2006 Jan; 28(1):237-44. PubMed ID: 16328001
[TBL] [Abstract][Full Text] [Related]
5. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
van Moorsel CJ; Pinedo HM; Veerman G; Guechev A; Smid K; Loves WJ; Vermorken JB; Postmus PE; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):407-15. PubMed ID: 9933029
[TBL] [Abstract][Full Text] [Related]
8. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair.
Dunkern TR; Fritz G; Kaina B
Mutat Res; 2001 Sep; 486(4):249-58. PubMed ID: 11516928
[TBL] [Abstract][Full Text] [Related]
10. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
11. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
Padrón JM; van Moorsel CJ; Bergman AM; Smitskamp-Wilms E; van der Wilt CL; Peters GJ
Anticancer Drugs; 1999 Jun; 10(5):445-52. PubMed ID: 10477163
[TBL] [Abstract][Full Text] [Related]
12. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
Van Moorsel CJ; Smid K; Voorn DA; Bergman AM; Pinedo HM; Peters GJ
Int J Oncol; 2003 Jan; 22(1):201-7. PubMed ID: 12469205
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line.
Fujishima H; Nakano S; Masumoto N; Esaki T; Tatsumoto T; Kondo T; Niho Y
Oncol Res; 1997; 9(4):167-72. PubMed ID: 9268987
[TBL] [Abstract][Full Text] [Related]
14. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
15. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
17. Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Huang P; Chubb S; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1991 Nov; 51(22):6110-7. PubMed ID: 1718594
[TBL] [Abstract][Full Text] [Related]
18. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
Moreland NJ; Illand M; Kim YT; Paul J; Brown R
Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
[TBL] [Abstract][Full Text] [Related]
19. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
van Moorsel CJ; Pinedo HM; Smid K; Comijn EM; Voorn DA; Veerman G; Lakerveld B; Van der Vijgh WJ; Giaccone G; Postmus PE; Peters GJ
Eur J Cancer; 2000 Dec; 36(18):2420-9. PubMed ID: 11094319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
